ES2102675T3 - Virus obtenible de celulas de neuroblastoma humanas. - Google Patents
Virus obtenible de celulas de neuroblastoma humanas.Info
- Publication number
- ES2102675T3 ES2102675T3 ES93919173T ES93919173T ES2102675T3 ES 2102675 T3 ES2102675 T3 ES 2102675T3 ES 93919173 T ES93919173 T ES 93919173T ES 93919173 T ES93919173 T ES 93919173T ES 2102675 T3 ES2102675 T3 ES 2102675T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- cells
- human
- rna
- neuroblastoma cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 7
- 206010029260 Neuroblastoma Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000000933 neural crest Anatomy 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LA INVENCION PROPORCIONA UN VIRUS DE ESTRUCTURA ICOSAHEDRAL QUE TIENE UN DIAMETRO DE UNOS 72 NM, RNA DE DOBLE TRENZADO EN SIETE SEGMENTOS DE PESOS MOLECULARES 4''0, 3''9, 2''3, 2''2, 1''6, 1''4 Y 1''3 KB, CAPACES DE INFECTAR CELULAS DE CRESTA NEURAL HUMANA Y OTRAS CELULAS ECTODERMALES HUMANAS, ORIGINA AMPLIFICACION N-MYC EN CELULAS INFECTADAS, Y ES OBTENIBLE DE CELULAS NEUROBLASTOMAS HUMANAS. LA INVENCION PROPORCIONA ADEMAS EL RNA DEL VIRUS Y EL DNA CORRESPONDIENTE AL MISMO, ASI COMO FRAGMENTOS DEL MISMO Y LINEAS CELULARES TRANSFERIDAS CON EL VIRUS. ANTIGENOS DE USO EN VACUNAS PUEDEN COMPRENDER FORMAS ATENUADAS O INACTIVAS DEL VIRUS. LA INVENCION SE EXTIENDE TAMBIEN A ANTICUERPOS CONTRA EL VIRUS Y EQUIPOS DE DIAGNOSTICOS PARA ENSAYO DE VIRUS, COMPRENDIENDO TALES ANTICUERPOS O ANTIGENO VIRAL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9218164A GB9218164D0 (en) | 1992-08-26 | 1992-08-26 | Virus and substances related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2102675T3 true ES2102675T3 (es) | 1997-08-01 |
Family
ID=10721003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93919173T Expired - Lifetime ES2102675T3 (es) | 1992-08-26 | 1993-08-25 | Virus obtenible de celulas de neuroblastoma humanas. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0658195B1 (es) |
| JP (1) | JPH08505760A (es) |
| AT (1) | ATE153375T1 (es) |
| AU (1) | AU681352B2 (es) |
| CA (1) | CA2142902A1 (es) |
| DE (1) | DE69310918T2 (es) |
| DK (1) | DK0658195T3 (es) |
| ES (1) | ES2102675T3 (es) |
| GB (1) | GB9218164D0 (es) |
| GR (1) | GR3024494T3 (es) |
| IL (1) | IL106793A0 (es) |
| WO (1) | WO1994004661A1 (es) |
| ZA (1) | ZA936163B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060040882A1 (en) | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| JP5536334B2 (ja) * | 2005-10-14 | 2014-07-02 | マリーナ バイオテック，インコーポレイテッド | Ｒｎａ治療用ペプチドリボ核酸縮合体粒子のための化合物及び方法 |
-
1992
- 1992-08-26 GB GB9218164A patent/GB9218164D0/en active Pending
-
1993
- 1993-08-23 ZA ZA936163A patent/ZA936163B/xx unknown
- 1993-08-24 IL IL106793A patent/IL106793A0/xx unknown
- 1993-08-25 DE DE69310918T patent/DE69310918T2/de not_active Expired - Fee Related
- 1993-08-25 WO PCT/EP1993/002291 patent/WO1994004661A1/en not_active Ceased
- 1993-08-25 ES ES93919173T patent/ES2102675T3/es not_active Expired - Lifetime
- 1993-08-25 CA CA 2142902 patent/CA2142902A1/en not_active Abandoned
- 1993-08-25 EP EP19930919173 patent/EP0658195B1/en not_active Expired - Lifetime
- 1993-08-25 AU AU49534/93A patent/AU681352B2/en not_active Ceased
- 1993-08-25 DK DK93919173T patent/DK0658195T3/da active
- 1993-08-25 AT AT93919173T patent/ATE153375T1/de active
- 1993-08-25 JP JP50592494A patent/JPH08505760A/ja active Pending
-
1997
- 1997-08-21 GR GR970402133T patent/GR3024494T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU681352B2 (en) | 1997-08-28 |
| WO1994004661A1 (en) | 1994-03-03 |
| CA2142902A1 (en) | 1994-03-03 |
| DE69310918D1 (de) | 1997-06-26 |
| JPH08505760A (ja) | 1996-06-25 |
| IL106793A0 (en) | 1993-12-08 |
| DK0658195T3 (da) | 1997-07-14 |
| ATE153375T1 (de) | 1997-06-15 |
| GR3024494T3 (en) | 1997-11-28 |
| EP0658195A1 (en) | 1995-06-21 |
| DE69310918T2 (de) | 1997-12-18 |
| EP0658195B1 (en) | 1997-05-21 |
| ZA936163B (en) | 1995-02-03 |
| AU4953493A (en) | 1994-03-15 |
| GB9218164D0 (en) | 1992-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deeba et al. | Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies | |
| Khan et al. | Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice | |
| ES2126620T3 (es) | Retrovirus del grupo de los vih y su utilizacion. | |
| Rothan et al. | The potential threat of multisystem inflammatory syndrome in children during the COVID‐19 pandemic | |
| Ahmed et al. | Inactivated vaccine Covaxin/BBV152: A systematic review | |
| ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
| ES2154738T3 (es) | Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora. | |
| DeZure et al. | Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus | |
| ES2083764T3 (es) | Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico. | |
| PT891420E (pt) | Processos para a replicacao dos virus influenza numa cultura celular e os virus influenza que se podem obter atraves do processo | |
| Zhu et al. | A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine | |
| CO4480039A1 (es) | Vacunas recombinantes de inmunodeficiencia felina producidas en baculovirus y su uso contra la infeccion de virus de inmunodeficiencia felina | |
| Piper et al. | Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice | |
| ES2074968B1 (es) | Nuevas cepas de pseudomonas aeruginosa atenuadas. | |
| PE72699A1 (es) | Antigeno del rotavirus, vacuna y agente diagnostico para infeccion por rotavirus y un metodo para producir el antigeno | |
| Araujo et al. | Antibodies to rabies virus in terrestrial wild mammals in native rainforest on the north coast of São Paulo State, Brazil | |
| Zayou et al. | A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4+ and CD8+ T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection | |
| ES2102675T3 (es) | Virus obtenible de celulas de neuroblastoma humanas. | |
| Bobrin et al. | Surface Inactivation of Highly Mutated SARS-CoV-2 Variants of Concern: Alpha, Delta, and Omicron | |
| JP5665899B2 (ja) | 癌の処置のための粘液腫ウイルス変異体 | |
| Taweechaisupapong et al. | Langerhans cell density and serological changes following intradermal immunisation of mice with dengue 2 virus | |
| AR124384A1 (es) | Parapoxvirus modificado que tiene inmunogenicidad aumentada | |
| Abd El-Baky et al. | Depending on epitope profile of COVID-19 mRNA vaccine recipients: Are they more efficient against the arising viral variants? An opinion article | |
| ATE283065T1 (de) | Mehrzweckvakzine gegen umhüllte viren | |
| ES2149182T3 (es) | Anticuerpo recombinante dirigido contra el calicivirus felino y fragmentos de genes de este anticuerpo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 658195 Country of ref document: ES |